

August 23, 2024

Termination of Exclusive Sales Rights Agreements for HGF Gene Therapy Product "Collategene®" in Japan and the US

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, announces the termination of its exclusive sales rights agreements with AnGes Inc (Head Office: Ibaraki, Osaka, President: Ei Yamada; hereinafter, "AnGes") for the HGF gene therapy product, Collategene® Intramuscular Injection 4 mg (Active ingredient: beperminogene perplasmid; hereinafter, "Collategene®") targeting peripheral arterial diseases in Japan and the United States.

In June 2024, AnGes withdrew its manufacturing and marketing approval application for Collategene® in Japan, and the conditional and time-limited marketing approval for the product expired. By this expiry, the distribution of Collategene® by MTPC has since been discontinued.

Under such situation, MTPC and AnGes have agreed to terminate these agreements effective on November 1, 2024, for Japan and on February 1, 2025, for the United States.

With the termination, AnGes regains the Japan and the United States exclusive sales rights related to Collategene® that were granted by AnGes to MTPC.

Contact:

Mitsubishi Tanabe Pharma Corporation
Pharma Business Strategy Division
PR Department
+81-6-6205-5119